Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3671105 | 0.82 | POLB (0.57) | POLBKMT2A | |
| SCHEMBL6399782 | 0.81 | L3MBTL1 (0.54) | LMNARAB9ANPC1L3MBTL1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6399092 | 0.80 | L3MBTL1 (0.53) | LMNARAB9ANPC1L3MBTL1SMN1; SMN2 | |
| SCHEMBL19912785 | 0.78 | RAB9A (0.63) | LMNARAB9ANPC1L3MBTL1SMN1; SMN2 | |
| SCHEMBL16671249 | 0.78 | RAB9A (0.63) | LMNARAB9ANPC1L3MBTL1SMN1; SMN2 | |
| SCHEMBL9265040 | 0.77 | RAB9A (0.79) | RAB9ANPC1L3MBTL1SMN1; SMN2HSD17B10 | |
| SCHEMBL6707186 | 0.77 | RAB9A (0.79) | RAB9ANPC1L3MBTL1SMN1; SMN2HSD17B10 | |
| SCHEMBL3675224 | 0.77 | PARP1 (0.52) | — | |
| SCHEMBL21257402 | 0.77 | SMYD3 (0.78) | LMNARAB9ANPC1L3MBTL1SMN1; SMN2 | |
| SCHEMBL12736080 | 0.75 | LMNA (0.56) | LMNARAB9ANPC1L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298377-A1 | NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-11-25 | — | — | US | claimed |
| EP-2170865-A2 | NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF, AND USE OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2010-04-07 | — | — | EP | claimed |
| WO-2009010660-A2 | SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF, AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2009-01-22 | — | — | WO | claimed |
| US-20100298377-A1 | NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-11-25 | — | — | US | disclosed |
| EP-2170865-A2 | NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF, AND USE OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009010660-A2 | SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF, AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298377-A1 | NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF AND USE OF SAME IN THERAPEUTICS | WEE1, PRMT1, ABL1 | LMNA 3126/4885RAB9A 716/4885NPC1 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.